Dyskeratosis Congenita Clinical Trials

Find Dyskeratosis Congenita Clinical Trials Near You

Pilot Study of Quercetin Patients With Dyskeratosis Congenita/Telomere Biology Disorders

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Healthy Volunteers: f
View:

• Diagnosis of DC/TBD deficiency as defined by at least one of the following:

‣ Age adjusted mean-telomere length of \<1 percentile in all tested peripheral blood cells such as granulocytes, lymphocytes, B-cells, naïve T-cells, memory T-cells, and NK cells

⁃ A pathogenic or likely pathogenic mutation in DKC1, TERC, TERT, NOP10, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53

• Patients ≥ 2.0 years of age\*

‣ The first three enrolled patients must be ≥ 10.0 years of age

• Able to take medication orally

Locations
United States
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Contact Information
Primary
Monica Trapp, BSN, RN, TCTCN
monica.trapp@cchmc.org
5138038574
Time Frame
Start Date: 2026-05-29
Estimated Completion Date: 2028-09
Participants
Target number of participants: 12
Treatments
Experimental: Quercetin
Quercetin dose (based on patient weight and as a percentage of adult dose - as noted in Table 2) will be given orally on a twice a day schedule starting with weight adjusted maximum total daily dose of 4000 mg/day (and administered in divided doses bid). For patients who weigh 70 kg or more, the starting dose will be automatically assigned at the maximum dose of 4000 mg/day.
Related Therapeutic Areas
Sponsors
Leads: Children's Hospital Medical Center, Cincinnati

This content was sourced from clinicaltrials.gov